Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORCHID: Benralizumab in Eosinophilic Chronic Rhinosinusitis with Nasal Polyps
2021-000267-72Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing Benralizumab with Placebo (2 arms). Primary endpoints: Change from baseline in endoscopic total nasal polyp score and Change from baseline in patient-reported nasal blockage. Started Jun 2021; status: active.
02
Drugs
benralizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on 2021-000267-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000267-72.